REGENXBIO Inc. (RGNX) research
REGENXBIO Inc.- Sector
- Biotechnology
- Last price
- $7.43
- As of
REGENXBIO Inc. (RGNX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-23.
As of . Source: SEC EDGAR filings for RGNX. Method and limitations.
Share the RGNX intelligence card
See the full RGNX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RGNX on one page. Preview it with sample data, then open it live with a free account.
Preview the RGNX dossierActive signals for RGNX
- highCONSENSUS_BUY
5 tracked funds increased RGNX this 2026Q2, institutional consensus
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 626.4%, EPS $0.43 vs $0.0592 estimate
- highCONSENSUS_BUY
3 tracked funds increased RGNX this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +69% to RGNX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +82% to RGNX (2026Q2)
FREE, NO ACCOUNT
Every signal on RGNX, as it fires
You are seeing 5 of 17 signals recorded on RGNX since 2026-05-26.
The five above landed across 3 days. The other 12 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RGNX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 75901B107 · 2026Q2 | $8.5M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 75901B107 · 2026Q2 | $8M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 75901B107 · 2026Q2 | $8M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 75901B107 · 2026Q2 | $5.8M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 75901B107 · 2026Q2 | $3.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RGNX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
RGNX against its peers
RGNX's operating margin of -94.6% ranks in the 65th percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | RGNX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 170M USD | 2.6M USD | 85 | 16 |
| Operating margin | -94.6% | -734.3% | 65 | 12 |
| Net margin | -113.8% | -887.0% | 65 | 12 |
| Return on equity | -188.7% | -47.0% | 7 | 21 |
Peers (22): ARVN, CTNM, AUTL, OVID, PBYI, ASMB, ENTX, EPRX, OCS, MNPR, CBIO, NGNE, DMAC, TECX, ALT, PRTA, INDP, PRME, CAPR, YDES, VALN, ALLO. Left out: DRUG (period gap), RLFTY (no annual filing), AGMB (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (RGNX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more RGNX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to RGNXand get the insider, 13F, options, and confluence read in one view.